Literature DB >> 18373500

Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review.

Nay Win1, Helen New, Edmond Lee, Josu de la Fuente.   

Abstract

BACKGROUND: Hyperhemolysis syndrome (HS) has been well described both in sickle cell disease (SCD) and non-SCD patients. The pathogenesis remains unclear. The possible mechanisms include bystander hemolysis, suppression of erythropoiesis, and destruction of red cells (RBCs) due to contact lysis via activated macrophages. CASE REPORT: This study reports a child with SCD who presented with recurrent episode of HS. In the first episode, the hemoglobin (Hb) level decreased to 4.1 g per dL. He was treated with intravenous immunoglobulin (IVIG) and oral steroids, and transfusion was avoided. Six months later he had another episode of HS. The nadir Hb level decreased to 3.2 g per dL, and further transfusions were given with IVIG-IV methylprednisolone cover.
RESULTS: RBC alloantibodies were not identified in pre- and posttransfusion samples in patient's serum in both episodes. HLA antibodies were also not detected.
CONCLUSION: This is the second reported case of recurrent HS in a child. Recent studies have shown that the adhesion molecules expressed on RBC erythroid precursor cells and reticulocytes can interact with macrophages and can cause hemolysis. Because RBC alloantibodies and HLA antibodies were not identified in this case, it is believed that the patient's cells and transfused cells were destroyed by macrophages either by direct contact lysis or by erythrophagocytosis. The possible mechanism of IVIG and steroids on suppression of macrophages resulting in cessation of hemolysis is discussed. Our case illustrates the danger of recurrent HS and the difficulty of balancing this against the need for transfusions in patients presented with severe hemolysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18373500     DOI: 10.1111/j.1537-2995.2008.01693.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  18 in total

Review 1.  Concise review: stem cell-derived erythrocytes as upcoming players in blood transfusion.

Authors:  Ann Zeuner; Fabrizio Martelli; Stefania Vaglio; Giulia Federici; Carolyn Whitsett; Anna Rita Migliaccio
Journal:  Stem Cells       Date:  2012-08       Impact factor: 6.277

2.  Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins.

Authors:  Stéphane Jauréguiberry; Papa A Ndour; Camille Roussel; Flavie Ader; Innocent Safeukui; Marie Nguyen; Sylvestre Biligui; Liliane Ciceron; Oussama Mouri; Eric Kendjo; François Bricaire; Muriel Vray; Adéla Angoulvant; Julien Mayaux; Kasturi Haldar; Dominique Mazier; Martin Danis; Eric Caumes; Marc Thellier; Pierre Buffet
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

3.  Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice.

Authors:  Connie M Arthur; Jerry William L Allen; Hans Verkerke; Justin Yoo; Ryan P Jajosky; Kathryn Girard-Pierce; Satheesh Chonat; Patricia Zerra; Cheryl Maier; Jen Rha; Ross Fasano; Cassandra D Josephson; John D Roback; Sean R Stowell
Journal:  Blood Adv       Date:  2021-01-26

Review 4.  Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease.

Authors:  Eric A Gehrie; Paul M Ness; Evan M Bloch; Seema Kacker; Aaron A R Tobian
Journal:  Transfusion       Date:  2017-06-26       Impact factor: 3.157

5.  Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival.

Authors:  Marilyn J Telen; Araba Afenyi-Annan; Melanie E Garrett; Martha R Combs; Eugene P Orringer; Allison E Ashley-Koch
Journal:  Transfusion       Date:  2014-12-01       Impact factor: 3.157

Review 6.  How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions.

Authors:  France Pirenne; Karina Yazdanbakhsh
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

Review 7.  Transfusion Support of Minority Patients: Extended Antigen Donor Typing and Recruitment of Minority Blood Donors.

Authors:  Jenna Khan; Meghan Delaney
Journal:  Transfus Med Hemother       Date:  2018-07-19       Impact factor: 3.747

8.  Stem cell-derived erythrocytes as upcoming players in blood transfusion.

Authors:  A R Migliaccio
Journal:  ISBT Sci Ser       Date:  2013-06

9.  HLA alloimmunization is associated with RBC antibodies in multiply transfused patients with sickle cell disease.

Authors:  Marianne E McPherson; Alan R Anderson; Marta-Inés Castillejo; Christopher D Hillyer; Robert A Bray; Howard M Gebel; Cassandra D Josephson
Journal:  Pediatr Blood Cancer       Date:  2010-04       Impact factor: 3.167

Review 10.  Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management.

Authors:  Karina Yazdanbakhsh; Russell E Ware; France Noizat-Pirenne
Journal:  Blood       Date:  2012-05-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.